To read this full article you need to be subscribed to Newsline.
Sign in Sign up for a FREE subscriptionSPONSORED: UBS Asset Management — Supply-demand imbalance makes life sciences sector ripe for investment
Venture capital stepped in to support life sciences companies as the pandemic added additional urgency to the sector’s need to develop medical solutions to global health problems. Beyond capital, life sciences companies need real estate space, customized to very specific tenant requirements. That’s where institutional capital can help to bring supply to meet demand, as European life sciences markets begin to catch up to more mature U.S. markets.
“On the supply side, there is basically no purpose-built modern laboratory space for growing companies across Europe. Any existing space is predominantly within university or hospital campuses, or in dated laboratories. There hasn’t been institutional-grade investment into developing life sciences space in Europe,” explains Zachary Gauge, head of European Research and Strategy Europe ex DACH at UBS Asset Management.
In an interview published in the June issues of Institutional Real Estate Americas and In
